Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EBT: 2020-2025

Historic EBT for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.

  • Fulcrum Therapeutics' EBT rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
  • Fulcrum Therapeutics' EBT amounted to -$19.6 million in Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
  • Fulcrum Therapeutics' EBT's 5-year high stood at $55.4 million during Q2 2024, with a 5-year trough of -$34.1 million in Q2 2022.
  • For the 3-year period, Fulcrum Therapeutics' EBT averaged around -$14.4 million, with its median value being -$22.7 million (2023).
  • Per our database at Business Quant, Fulcrum Therapeutics' EBT spiked by 332.98% in 2024 and then crashed by 131.86% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' EBT (Quarterly) stood at -$23.5 million in 2021, then declined by 11.29% to -$26.1 million in 2022, then increased by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then increased by 9.68% to -$19.6 million in 2025.
  • Its EBT stands at -$19.6 million for Q3 2025, versus -$17.7 million for Q2 2025 and -$16.6 million for Q4 2024.